Clinical and laboratory follow-up in differentiated thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology

Background:

• Thyroid carcinoma is the most common endocrine malignancy, primarily differentiated types (papillary and follicular), accounting for over 90% of cases.
• Long-term patient follow-up is essential due to the potential for late recurrence of differentiated thyroid carcinoma.

Purpose of the Study:

• To highlight the role of thyroglobulin as a key tumor marker in differentiated thyroid carcinoma management.
• To emphasize the necessity of simultaneous antithyroglobulin antibody determination for accurate thyroglobulin assay interpretation.

Main Methods:

• Monitoring differentiated thyroid carcinoma patients using thyroglobulin levels.
• Assessing thyroglobulin levels during L-thyroxine therapy, withdrawal, or after recombinant TSH administration.
• Measuring antithyroglobulin antibodies concurrently with thyroglobulin to address potential interference.

Main Results:

• Thyroglobulin serves as a vital organ-specific tumor marker for differentiated thyroid carcinoma.
• Antithyroglobulin antibodies can mask the true thyroglobulin levels, leading to inaccurate assessments.
• Simultaneous measurement of antithyroglobulin antibodies is critical for reliable thyroglobulin-based monitoring.

Conclusions:

• Thyroglobulin is indispensable for the lifelong follow-up of differentiated thyroid carcinoma patients.
• Accurate interpretation of thyroglobulin tumor marker levels necessitates concurrent testing for antithyroglobulin antibodies.
• This dual testing approach ensures reliable disease surveillance and management in thyroid cancer survivors.